A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded an increase of 115.79%. However, over the last six months, the performance has been weaker by 120.77%. The price of XERS increased 29.86% over the last 30 days. And in the last five days, it has surged by 2.50%.
Xeris Biopharma Holdings Inc. (XERS) current stock price is $2.87. During the last trading session, the stock soared, reaching $2.92 after opening at $2.75. The stock’s lowest point was $2.72 before it closed at $2.79.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Xeris Biopharma Holdings Inc.’s stock has had a calm market performance. The 1-year high for the company’s stock was $3.03 on 05/12/23, and the lowest price during the same period was recorded at $0.97 on 01/05/23.
52-week price history of XERS Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Xeris Biopharma Holdings Inc.’s current trading price is -5.25% away from its 52-week high, while its distance from the 52-week low is 195.85%. The stock’s price range over this timeframe has been between $0.97 and $3.03. The shares of the Healthcare sector company recorded a trading volume of approximately 0.73 million for the day, which was comparatively lower than the average daily volume of 1.34 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Xeris Biopharma Holdings Inc. (XERS) has experienced a quarterly rise of 133.33% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 381.80M and boasts a workforce of 355 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.68, with a change in price of +1.62. Similarly, Xeris Biopharma Holdings Inc. recorded 1,263,652 in trading volume during the last 100 days, posting a change of +129.60%.
XERS’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for XERS stands at 6.25. Similarly, the long-term debt-to-equity ratio is also 6.25.
XERS Stock Stochastic Average
The raw stochastic average for Xeris Biopharma Holdings Inc. over the last 50 days is presently at 91.07%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 82.89%. Further, the company’s Stochastic %K and %D values for the last 20 days were 82.89% and 83.85%, respectively.
